Motor

BIOGEN IDEC AND ABBVIE ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING DACLIZUMAB HIGH-YIELD PROCESS IN MULTIPLE SCLEROSIS

17-06-2014 13:58 CEST Biogen Idec Norway AS ? DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate ? ? Positive Results Set Stage for Regulatory Filings

17-06-2014 13:58 CEST Biogen Idec Norway AS ? DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate ? ? Positive Results Set Stage for Regulatory Filings ?

Artykuly o tym samym temacie, podobne tematy